Loading company
Outlook Therapeutics, Inc.
OTLK · Nasdaq · ·
$0.63+0.4%Sep 29 close
- 1M
- -2.9%
- 6M
- +211.6%
- 1Y
- -40.9%
- 5Y
- -98.6%
OTLK · Nasdaq · ·
$0.63+0.4%Sep 29 close
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $8.7K | $1.5M | -99.42% |
| Profit | -$20.3M | -$20.2M | -0.83% |
| Profit per share | -$0.15 | -$0.55 | +72.73% |
| Free Cash Flow | -$5.9M | -$9.7M | +38.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Outlook Therapeutics, Inc. has no earnings call transcript available.
“FDA approval of LYTENAVA marks a defining moment for Outlook Therapeutics and creates a significant opportunity for the Company in the United States,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
The quote and the company description come from Outlook Therapeutics, Inc.’s Item 2.02 8-K filed August 14, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.